Toronto, Ontario – May 7, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the Chinese Patent Office has Issued a Notice of Acceptance for a patent application concerning Multiwavelength PhotoDynamic Therapy (“PDT”) to the Company. The patent entitled, “Apparatus and Method for Multiwavelength PhotoDynamic Therapy” validates the proprietary position of the Company and opens opportunities for the application of Theralase’s PDT technology in an international market. Kipton P. Lade, CEO – Device Division, Theralase stated, “Theralase continues to advance it’s Anti-Cancer Therapy (“ACT”) through optimization of the technology and protecting those advancements through a comprehensive intellectual property strategy. This new multiwavelength laser system is the latest addition to our technology platform, … Read More

Toronto, Ontario – May 6, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce the Company’s Anti-Cancer Therapy (“ACT”) for Non-Muscle Invasive Bladder Cancer (“NMIBC”) in a Phase Ib clinical study, was selected for presentation at the American Urological Association (“AUA”) conference, held in Chicago, Illinois on May 3rd to May 6th, 2019. The AUA is a premier urologic association, that provides invaluable support to the urologic community, with a mission to promote the highest standards of urological clinical care through education, research and the formulation of health care policy. The annual AUA conference brings together medical professionals and researchers from around the globe to discuss and present the latest advances in urological … Read More

Toronto, Ontario – April 25, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTCQB), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers, announced today that the University Health Network Research Ethics Board (“UHN-REB”) has approved the commencement of a Phase II clinical study to evaluate Theralase’s Anti-Cancer Treatment (“ACT”) titled, “Patients with Non-Muscle Invasive Bladder Cancer (“NMIBC”), who present with Carcinoma In-Situ (“CIS”), who are considered Bacillus Calmette Guérin (“BCG”) – Unresponsive or are intolerant to BCG Therapy (“ACT-NMIBC”)”. The ACT-NMIBC study has been designed in compliance with FDA industry guidelines issued February, 2018 for BCG-unresponsive NMIBC. The study will utilize the Therapeutic Dose (0.70 mg/cm) of TLD-1433 and will focus on the treatment of approximately 100 to 125 BCG-unresponsive NMIBC patients, with CIS, in approximately … Read More

Nine Scientific Papers Detailing the Latest Scientific Research of Theralase®’s Anti-Cancer Technology (“ACT”) Platform have been Peer Reviewed and will be Presented at the International Photodynamic Association World Congress Toronto, Ontario – April 15, 2019, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce nine scientific papers pertaining to the Company’s Anti-Cancer Technology (“ACT”) Platform and Rutherrin® based Photo Dynamic Therapy (“PDT”) have been peer reviewed and selected for presentation at the 17th Annual International Photodynamic Association (“IPA”) World Congress, to be held in Cambridge, Massachusetts, USA from June 28th to July 4th, 2019. IPA has been bringing together researchers and clinicians in all fields of PDT and PhotoDiagnosis (“PD”) since 1986. Every … Read More

Results of Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study Demonstrate a 66% Complete Response (“CR”) at the Therapeutic Dose (0.70 mg/cm2) 360 Days Post Treatment Toronto, Ontario –April 2, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to report that patient six, enrolled and treated in the recently completed Phase Ib NMIBC Clinical Study (“Study”), has demonstrated a CR with no tumour recurrence, progression or presence of NMIBC disease at the 360 day clinical and cystoscopy assessment. The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of … Read More

Toronto, Ontario – March 26, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the results of the Phase Ib clinical study will be presented at the 17th International Photodynamic Association (“IPA”) World Congress, to be held in Cambridge, Massachusetts from June 28th to July 4th, 2019. IPA has been bringing together researchers and clinicians in all fields of PhotoDynamic Therapy (“PDT”) and PhotoDiagnosis (“PD”) since 1986. Every two years, the IPA organizes a conference to foster scientific development and contribute to clinical practice, ultimately capturing the current status of the field. This year, Lother Lilge, Ph.D., Professor of Medical Biophysics at the University of Toronto, an esteemed PDT expert and a … Read More

Toronto, Ontario – March 4, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers, announced today that it has been granted allowance for a United States patent to issue later this year for destroying cancer cells with X-ray activated PDCs. The new patent to issue later this year is entitled, “Photodynamic Compounds and Methods for Activating Them Using Ionizing Radiation and/or Other Electromagnetic Radiation for Therapy and/or Diagnostics” Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® and the lead inventor of the technology stated that, “In 2019, the Company plans to commence a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) clinical study, which if successful may lead to commercialization of this technology in Canada, the United States … Read More

Toronto, Ontario – February 28, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has been named third place on the 2019 TSX Venture 50TM in the Clean Technology & Life Sciences sector amongst all TSX Venture Exchange listed companies. The ranking is comprised of ten companies from each of five industry sectors, selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume amount. Theralase is a previous winner of the 2015 TSX Venture 50TM. Dr. Shawn Shirazi, Ph.D., Chief Executive Officer – Drug Division, Theralase® stated that, “Theralase’s achievement of third place in the 2019 TSX Venture 50TM top performing companies is a strong indication of the value that the Company … Read More

Toronto, Ontario – February 25, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce the appointment of Shawn Shirazi, Ph.D., to the role of CEO of Theralase’s Drug Division (“CEO-Drug”) and Kipton Lade, B.Sc., M.Sc., MBA., to the role of Chief Executive Officer (“CEO”) of Theralase’s Device Division (“CEO-Device”). Shawn Shirazi, Ph.D. Pharmacology obtained his B.Sc. in Chemistry from York University (Toronto, Ontario, Canada) and a M.Sc. and Ph.D. in Pharmacology from the University of Ottawa (Ottawa, Ontario, Canada). Dr. Shirazi brings over 20 years of hands-on experience in: pharmaceutical drug formulation and development, clinical trial management, Good Manufacturing Practices (“GMP”) international drug manufacture, international regulatory guidelines and quality assurance in GMP drug manufacture. He … Read More

Toronto, Ontario – January 31, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”), has demonstrated no tumour recurrence or presence of disease at the 360 day clinical and cystoscopy assessment. The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment. The Study was successfully completed with patient five and six demonstrating achievement of the primary, secondary and exploratory endpoints. … Read More